Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors

NCT01841736 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01841736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01841736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 20, 2013
Completion date
September 10, 2027
Enrollment
171 (actual)
Sites
423

Conditions

As the registry lists them; a condition with its own page is linked.

foregut neuroendocrine tumor, hindgut neuroendocrine tumor, metastatic digestive system neuroendocrine tumor g1, metastatic neuroendocrine tumor, midgut neuroendocrine tumor g1, neuroendocrine tumor g2, recurrent digestive system neuroendocrine tumor g1, regional digestive system neuroendocrine tumor g1